FDA Offers Guidance on Risk-Based Trial Monitoring for Phase II, IV

Source: PharmaManufacturing.com

Aug 12, 2013

in-Pharma Technologist.com

The US FDA has finalized guidance on clinical trial oversight, calling for more remote and targeted risk-based monitoring, though some experts believe such monitoring should be more judiciously employed. Read the full story
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments